
Mike Garrett is a Sector Specialist in the Healthcare practice focusing primarily on biotechnology and pharmaceutical companies. Mike is also a Principal at TCG, a business development and interim management consulting firm specializing in medical devices, diagnostics and biotechnology.
From 2006 to 2014, Mike was Vice President of Corporate and Strategic Development at Scynexis, Inc., most recently as a member of the team that executed the company’s $62M IPO.
From 2004 to 2006, Mike was a Managing Director of Pharmavent Partners, a European Life Sciences venture capital fund headquartered in Paris, where he was responsible for UK-based investment opportunities. From 2001 to 2004, he was Global Vice President, Ventures & Business Development for BTG plc, a FTSE-250 company with responsibility for the company’s portfolio of more than 15 investments in early stage to public companies. Prior to this Mike worked in the corporate venture group of Aventis (Paris) and in their business development group. Earlier in his career he was a patent attorney in the Rhone-Poulenc Intellectual Property department, based in France and the UK.
Mike is a British and European Patent Attorney, holds an Honors degree in Chemistry from Southampton University, UK and an Executive Certificate in General Management from the Cedep INSEAD business school, France.
Securities Products and Investment Banking Services are offered through BA Securities, LLC. Member FINRA SIPC. Daybreak Capital Partners LLC and BA Securities, LLC are separate, unaffiliated entities. To learn more about the professional background of Daybreak Capital Partners LLC and our Registered Representatives, please visit FINRA BrokerCheck.
Past performance, awards, or testimonials are not indicative of future results. No guarantee of future performance or success is implied. Copyright © 2026 Daybreak Capital Partners LLC